Product
ABL001
Aliases
asciminib
Name
SCEMBLIX
INN Name
asciminib
FDA Approved
Yes
3 clinical trials
1 organization
4 indications
1 document
Indication
Chronic Myelogenous LeukemiaIndication
B-cell Acute Lymphoblastic LeukemiaIndication
Ph+ ALLClinical trial
A Phase 3b, Multi-center, Open-label, Treatment Optimization Study of Oral Asciminib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Previously Treated With 2 or More Tyrosine Kinase Inhibitors.Status: Active (not recruiting), Estimated PCD: 2024-06-28
Clinical trial
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I MutationStatus: Active (not recruiting), Estimated PCD: 2023-06-20
Clinical trial
A Phase 1 Study of ABL001 in Combination With Dasatinib, Prednisone, and Blinatumomab in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)Status: Recruiting, Estimated PCD: 2025-11-01
Document
DailyMed Label: SCEMBLIXOrganization
Novartis Pharmaceuticals Corporation